Top Markets
#1 OriginTrail OriginTrail +32.77%
#2 Waves Waves +12.71%
#3 Siren Siren +9.32%
#4 Pons Pons +7.56%
#5 BasedHype BasedHype +7.52%
#6 PulseChain PulseChain +5.89%
#7 TROLL TROLL +5.79%
#8 MarsCoin MarsCoin +5.70%
#9 Raydium Raydium +5.44%
#10 The Black Bull The Black Bull +5.34%
Coin of the day
OriginTrail OriginTrail
Settings
Language
ENGLISH
Currency
USD
Theme
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Chunghwa Chemical Synthesis & Biotech Co., Ltd.

Chunghwa Chemical Synthesis & Biotech Co., Ltd.

1762
Rank in Stocks #22434
Based in New Taipei City, Taiwan, Chunghwa Chemical Synthesis & Biotech Co.,... Based in New Taipei City, Taiwan, Chunghwa Chemical Synthesis & Biotech Co., Ltd., established in 1964 and previously known as China Chemical Synthesis Industry Co., Ltd., specializes in the development, production, and distribution of active pharmaceutical ingredients (APIs). The company's market reach includes Taiwan and the United States. Their API portfolio encompasses products designed for immunosuppression, oncology, and cardiovascular conditions, in addition to various peptide compounds. Moreover, they manufacture a wide array of bulk pharmaceutical substances for numerous therapeutic applications, including anti-anxiety agents, antidiabetics, laxatives, antifungals, antihistamines, antiseptics, antiulcerants, cardiovascular medications, skeletal muscle relaxants, hypolipidemics, antineoplastics, antihyperlipidemics, and immunosuppressants. Complementing its product offerings, Chunghwa Chemical Synthesis & Biotech delivers bespoke research and development as well as contract manufacturing services to both emerging drug developers and established generic pharmaceutical firms.
Share Price
$1.15
Last synced: 2026-08-21
Market Cap
$88.79M
Change (1 day)
2.54%
Change (1 year)
27.30%
Country
TW
Trade Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762)

Category

Healthcare
Revenue for Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762)
Revenue in Aug 2026 TTM: 0
According to Chunghwa Chemical Synthesis & Biotech Co., Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Chunghwa Chemical Synthesis & Biotech Co., Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $2.54B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $830.81M -
US
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT